FDA grants 'breakthrough' status to Portola’s andexanet alfa
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough designation status to Portola Pharmaceuticals' andexanet alfa, an investigational Factor Xa inhibitor antidote – news that boosted the firm's shares by 6.65% on 25 November.